To compare two dosages of low-molecular-weight heparin with placebo in the treatment of ischemic stroke.
- Nadroparin (Fraxiparine®)Drug
Intervention Desc: Antithrombotic (low molecular weight heparin)
- LMW heparin Drug
Intervention Desc: Low molecular weight heparin and heparinoids. See also specific compounds, including danaparoid, dalteparin, enoxaparin, nadroparin, tinzaparin.
Randomized, double-blind, placebo-controlled trial. 2750 patients were initially screened and 312 were randomized.
Patients were randomly assigned to receive high-dose nadroparin (4100 anti-factor Xa IU twice daily), low-dose nadroparin (4100 IU once daily), or placebo subcutaneously for 10 days.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Death or dependency regarding activities of daily living 6 months after randomization, assessed by telephone interview.|
|Secondary||Death, hemorrhagic transformation of the infarction, and other complications at 10 days, and death or dependency at 3 months.|